News
ANAB
14.60
+9.28%
1.24
Weekly Report: what happened at ANAB last week (1223-1227)?
Weekly Report · 12/30/2024 09:16
Weekly Report: what happened at ANAB last week (1216-1220)?
Weekly Report · 12/23/2024 09:17
AnaptysBio Price Target Cut to $36.00/Share From $66.00 by JP Morgan
Dow Jones · 12/19/2024 17:15
AnaptysBio Is Maintained at Overweight by JP Morgan
Dow Jones · 12/19/2024 17:15
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36
Benzinga · 12/19/2024 17:05
ANAPTYSBIO INC <ANAB.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $20 FROM $30
Reuters · 12/19/2024 12:05
AnaptysBio price target lowered to $36 from $66 at JPMorgan
TipRanks · 12/19/2024 11:40
U.S. RESEARCH ROUNDUP-Amazon, Mastercard, Tesla
Reuters · 12/19/2024 06:58
ANAPTYSBIO INC <ANAB.O>: JP MORGAN CUTS TARGET PRICE TO $36 FROM $66
Reuters · 12/19/2024 05:19
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)
Benzinga · 12/18/2024 22:00
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout
Seeking Alpha · 12/18/2024 21:24
AnaptysBio Price Target Cut to $20.00/Share From $30.00 by Truist Securities
Dow Jones · 12/18/2024 17:04
AnaptysBio Is Maintained at Hold by Truist Securities
Dow Jones · 12/18/2024 17:04
Truist Securities Maintains Hold on AnaptysBio, Lowers Price Target to $20
Benzinga · 12/18/2024 16:54
AnaptysBio price target lowered to $20 from $30 at Truist
TipRanks · 12/18/2024 15:15
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
NASDAQ · 12/18/2024 14:23
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
NASDAQ · 12/17/2024 15:43
Stifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)
TipRanks · 12/17/2024 02:05
Weekly Report: what happened at ANAB last week (1209-1213)?
Weekly Report · 12/16/2024 09:17
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)
TipRanks · 12/16/2024 05:50
More
Webull provides a variety of real-time ANAB stock news. You can receive the latest news about Anaptysbio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.